Manufacturers urge German government to revise proposals for pricing new drugsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e4069 (Published 13 June 2012) Cite this as: BMJ 2012;344:e4069
- Ned Stafford
Europe’s pharmaceutical industry has appealed to the German government to take “urgent action” to revise the German model for assessing the benefits of new drugs and setting their prices.
In a joint press release the European Federation of Pharmaceutical Industries and Associations and the German Association of Research Based Pharmaceutical Companies said that the reference pricing system now in use “is being used to force German pricing for new medicines towards generic prices.”
“Recent years have seen the introduction of a series of punitive measures in Germany,” said Richard Bergström, director general of the European federation. Specifically, he noted mandatory rebates paid by drug firms to public health insurers; an international reference pricing system that links German prices to “countries like Greece”; and a national …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial